ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,967.23
-0.88%
US Tech 100
16,554.00
-2.26%
Dow Jones
37,986.40
0.56%
Brent Oil
86.625
0.00%
Bitcoin
64,077.97
0.40%
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Protara Therapeutics Inc (TARA) Quote

Protara Therapeutics Inc

Protara Therapeutics Inc (TARA)

NASDAQ
2.64
-0.11
(-4.00%)
Closed April 20 4:00PM
Delayed by 15 minutes
2.61
-0.03
(-1.14%)
After Hours: 7:59PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.64
Bid
2.01
Ask
2.72
Volume
207,962
2.61 Day's Range 2.795
1.04 52 Week Range 5.10
Market Cap
9.604M
Previous Close
2.75
Open
2.71
Last Trade
75
@
2.73
Last Trade Time
Financial Volume
$ 556,137
VWAP
2.6742
Average Volume (3m)
227,026
Shares Outstanding
11,433,837
Dividend Yield
-
PE Ratio
-0.24
Earnings Per Share (EPS)
-3.54
Revenue
-
Net Profit
-40.42M

About Protara Therapeutics Inc

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatmen... Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
protaratx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Protara Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TARA. The last closing price for Protara Therapeutics was $2.75. Over the last year, Protara Therapeutics shares have traded in a share price range of $ 1.04 to $ 5.10.

Protara Therapeutics currently has 11,433,837 shares outstanding. The market capitalization of Protara Therapeutics is $9.60 million. Protara Therapeutics has a price to earnings ratio (PE ratio) of -0.24.

TARA Latest News

More News

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...

April 05 2024
GlobeNewswire Inc.

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline...

April 05 2024
GlobeNewswire Inc.

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive/Experienced patients in ongoing NMIBC programTARA-002 demonstrated a complete response rate of 63% at...

April 05 2024
GlobeNewswire Inc.

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with...

March 13 2024
GlobeNewswire Inc.

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...

February 28 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

January 23 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 23 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 23 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 23 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 23 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.43-14.0065146583.073.152.611592942.81889934CS
4-1.32-33.33333333333.965.12.615089473.55210345CS
120.218.641975308642.435.12.422270263.59866881CS
261.0768.1528662421.575.11.041358073.16005246CS
52-0.4-13.15789473683.045.11.04821803.07282633CS
156-12.98-83.098591549315.6215.951.04878975.84834643CS
260-22.56-89.523809523825.267.0791.04799409.4287738CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

TARA Discussion

View Posts
stocksrising stocksrising 2 weeks ago
Almost 100% increase in share count( major dilution) …Market Cap pre offering ~$46mm and Post equals ~$75mm( todays price)…yes, better balance sheet, positive interim data..all in all good news, but Arbs will mess around for a bit until Funds buy again…
Jesse is pretty good steward of capital, so when q1 is reported we will see what intrinsic value is ..GLTA
👍️0
TIMGZ TIMGZ 2 weeks ago
sometimes have to read btw the lines*****biotech*****trial,clinical trials will taketimeand money. longtimeinvestment mosttimes
👍️0
Roadtojourney Roadtojourney 2 weeks ago
Why would it go red even with all the good news??
👍️0
Monksdream Monksdream 2 weeks ago
Will it grow legs after 9:30
👍️0
TIMGZ TIMGZ 2 weeks ago
WHY NOT AT $9
👍️0
Awl416 Awl416 2 weeks ago
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
👍️0
dinogreeves dinogreeves 3 weeks ago
I know Monk, this should hit 5 before data. On another note ANV*S had their 10K today.
👍️0
Monksdream Monksdream 3 weeks ago
TARA under $4
👍️0
Poundthetable Poundthetable 3 weeks ago
Agreed everything in due time with TARA
👍️0
dinogreeves dinogreeves 3 weeks ago
Only a few months left for the data to be released.
👍️0
dinogreeves dinogreeves 1 month ago
I guess, I live in your head rent free now stupid peasant. Listen I just had lovely dinner and about to take a crap, going to think of you while I am taking a crap, with your mouth full open while I take a crap in it. Send whatever you want to the SEC, lets see what you got, you think they will listen to a peasant like you?
👍️0
jdcpa1 jdcpa1 1 month ago
Send the SEC your posts and your sell tickets so they can match them up.. pump and dump artist..
👍️0
dinogreeves dinogreeves 1 month ago
Save them all dumb peasant. I helped the SEC nail Alex Delarge you peasant.
👍️0
jdcpa1 jdcpa1 1 month ago
Ok saving your post for the SEC. Thanks dummy
👍️ 1 💎 1 💯 1
dinogreeves dinogreeves 1 month ago
This is going to hit the teens after the data read out moron. Furthermore this is a nasdaq stock not the scams you are accustomed to peasant.
👍️0
jdcpa1 jdcpa1 1 month ago
Beware folks.. there are pumpers with price predictions on here looking to close positions as they pump.. just my opinion but I think it's true.. any posts by predictors are suspect.. they are likely looking to sell..
👍️0
dinogreeves dinogreeves 1 month ago
TARA 5 to 6 dollars before data readout.
👍️0
dinogreeves dinogreeves 1 month ago
TARA 5-6 before data release, then once the data is confirmed easy will see the teens.
👍️0
Poundthetable Poundthetable 1 month ago
I been adding all the way down I like the potential here on this one fingers crossed
👍️0
dinogreeves dinogreeves 1 month ago
Hey bud, I don't have subscription anymore and refuse to pay, don't need it anymore. You got to stick out with this one and add when and if you can, news pending and they investor conference tomorrow.
👍️0
glenn1919 glenn1919 2 months ago
TARA......................................https://stockcharts.com/h-sc/ui?s=TARA&p=D&yr=0&mn=2&dy=12&id=p84071410134
👍️0
Poundthetable Poundthetable 2 months ago
Yup buying opportunities await
👍️0
dinogreeves dinogreeves 2 months ago
Wait couple of more days to add.
👍️0
dinogreeves dinogreeves 2 months ago
TARA has done exceptionally well. Only a matter of time.
👍️0
Poundthetable Poundthetable 2 months ago
Sounds good in it here 4 future growth
👍️0
dinogreeves dinogreeves 2 months ago
Data comes out positive look out above pound. Baker Brother still in the game and that is all we need to know.
👍️0
Poundthetable Poundthetable 2 months ago
Looks good Dino thanks 4 posting alert
👍️0
dinogreeves dinogreeves 2 months ago
Great action here pound. Should hit 5-6 before news.
👍️0
dinogreeves dinogreeves 2 months ago
They probably left last year, like you said for tax harvesting, it does look like it though, the stock bottoming in the low 1.05 range, which killed the stock, but it is coming back after it bottomed. Simple logic tells me, they have 300 million dollar shelf offering right now in the pipe line and there is no way they can do it here, so I think they have colluded with the market makers to drive the price higher, 5-6 dollars before news or even higher, no one knows their trick except for themselves, it would not make sense to sell securities in this range when the volume is anemic. Take a look at MDG*L chart, started at 5 range and shot up to 300-400 dollars in less than week, that one also has Baker Brothers in it and I believe it is also bladder and Liver cancer issues. Bottom line, if these ticker has the science, it will do wonders. 4 billion market cap vs 40 million market cap, so I say easily by June we can get to double digits.
👍️0
stocksrising stocksrising 2 months ago
Maybe Just year end for tax harvesting ( if they can even benefit ) or YE portfolio shuffling….they were probably leaning it all the way down to $1.5 where I picked up a bunch ( sold some too early last week @ $3.55 ( can’t argue with taken a profit) …still my largest position and will hold until we get double digits ! Jesse was at those 2 conferences, plus the Bakers ( like you said, and totally agree) helps…
Data readouts coming soon ( prob by May)
👍️0
dinogreeves dinogreeves 2 months ago
Looks like they sold. Orbimed is not as important as Baker Brothers to me, but I am curious though why Orbimed sold, we won't know until the results come out.
👍️0
stocksrising stocksrising 2 months ago
OrbiMed filed 13g/a but can’t tell if they added or sold??
👍️0
dinogreeves dinogreeves 2 months ago
TARA will see the teens fairly soon.
👍️ 2
dinogreeves dinogreeves 2 months ago
TARA moving nicely, should be around $5.00 before the results.
👍️0
stocksrising stocksrising 3 months ago
Maybe we get a bump from Conf’s:

Protara Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire 07:30AM ET, 01/31/2024
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
• Guggenheim Healthcare Talks 6th
Annual Biotechnology Conference. A fireside chat will take place on Wednesday, February 7, 2024 at
10:30 am ET in New York.
• Oppenheimer 34th Annual Healthcare Life Sciences Conference. A fireside chat will take place virtually on Wednesday, February 14, 2024 at
8:40 am ET.
👍️0
stocksrising stocksrising 3 months ago
Yep, agreed ✔️
👍️0
glenn1919 glenn1919 3 months ago
TARA.................................https://stockcharts.com/h-sc/ui?s=TARA&p=W&b=5&g=0&id=p86431144783
👍️0
dinogreeves dinogreeves 3 months ago
Orbimed and Baker Brothers is all you need to know. This will hit high double digits between March and June, maybe even sooner.
👍️0
dinogreeves dinogreeves 3 months ago
This is a good one bud, still holding and waiting on that big news.
👍️0
stocksrising stocksrising 3 months ago
Looking forward hopefully to seeing some 13G/A’s, insider purchases, etc…Data readouts prob early Q2, maybe even late Q1 :)

Jesse keeps cash burn low, and RSU’s are reasonable to employees!!

Intrinsic value( after cash burn end of 2023) of perhaps $3.5-4per share( fully diluted share count about 18mm*)($50mm collecting interest income )

10k & Q prob out in March , should be good reading material

*series 1 preferred 8000sh can convert
👍️0
dinogreeves dinogreeves 4 months ago
Awesome, you can't got wrong with these prices, just buy slowly, this should organically grow its wings. Bladder cancer market is huge, companies with more advance trials are worth billions. There is a reason why Baker Brothers is here, I think at some point next year they will increase their position, once this years taxes are done, it will be a great year next year for this.
💩 1 🤡 1 🤥 1
eur06 eur06 4 months ago
Got a starter!
Thank you for sharing.
👍️0
dinogreeves dinogreeves 4 months ago
I love this one very much, primarily because Baker Brothers owns this too, the other reason is severely undervalued.
👍️0
dinogreeves dinogreeves 4 months ago
Baker Brothers is on board. Extremely undervalued biotech in their hands, huge cash in the coffers and solid pipeline, I don't see these prices here much longer. Based on cash on hands, the stock is worth around 5-6 dollars, give it a months this will be in high single digit dollars.
👍️0
stocksrising stocksrising 1 year ago
OrbiMed Advisors now holds 6%+ .. Opaleye 25+, and Insiders 10%+… other funds total 20%+ aggregated…float is locked up, will go parabolic if ph1/B announced in Q2.. I’ve been buying under $3.5 for weeks now..You still playing ticker??
👍️0
stocksrising stocksrising 2 years ago
Opal almost at 25% ownership! Continue to scoop in the $6’s.
👍️0
stocksrising stocksrising 2 years ago
Opal continues open market accumulation around 7ish:)…see recent form 4’s

👍️0
stocksrising stocksrising 2 years ago
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $34
👍️0
stocksrising stocksrising 3 years ago
True!! This piggy never holds its gains, but I’m still in it for a 2022/23 payoff
👍️0
alchemytrader alchemytrader 3 years ago
nothing to cheer about.
👍️0

Your Recent History

NASDAQ
TARA
Protara Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved